This Study is a Prospective, Multi-center, Real World, Observational Study, Which Aims at
This study is a prospective, multi-center, real world, observational study, which aims at evaluating the intermediate and long-term efficacy of endovascular treatment for TASC C\&D aortoiliac occlusive disease .It is estimated that 800 subjects diagnosed with TASC C\&D aortoiliac occlusive disease and receive endovascu
| Condition(s) | Peripheral Arterial Disease |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study is a prospective, multi-center, real world, observational study, which aims at evaluating the intermediate and long-term efficacy of endovascular treatment for TASC C\&D aortoiliac occlusive disease .It is estimated that 800 subjects diagnosed with TASC C\&D aortoiliac occlusive disease and receive endovascular treatments will be enrolled in nine centers from April 2021 to June 2027 nation-widely. All the subjects will be under follow-up for 60 months. There is no restriction on the endovascular techniques. The primary outcomes covers freedom from TLR at 60 months. |
| Who can participate | Inclusion Criteria: 1. Rutherford grades 3-6. 2. Follow the follow-up arrangement. 3. Age: 18-80 years old. 4. The target lesions were in the lower abdominal aorta and/or the common iliac artery and/or the external iliac artery. 5. The stenosis degree ≥50%, or restenosis (received PTA or other adjuvant therapy, including bare or covers stents), or complete occlusion, or the presence of aortailiac artery thrombosis after PMT or CDT thrombus clearance, and then further endovascular therapy perfomred. 6. Signed informed consent. Exclusion Criteria: 1. Known allergy to drugs used in this study, including antiplatelet or anticoagulant drugs, etc. 2. Allergy to iodine contrast agent allergy; 3. Coagulation dysfunction or hypercoagulability; 4. Breast-feeding or pregnant women; 5. Life expectancy |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Shanghai Zhongshan Hospital |
| Locations | Shanghai, China |
| Start date | 2021-04-01 |
| NCT ID | NCT05391815 |
| Official listing | https://clinicaltrials.gov/study/NCT05391815 |